ST. JOSEPH, Mich., Feb. 27 /- GeneGo, Inc., the leading systems biology tools company, announced today the release of a new product, 1-2-3 Workflow(TM), accessible via a "pay-as-you-go" model. This easy to use workflow provides casual users with an automated comprehensive functional analysis of multiple gene lists in just two clicks. All the processing is done in the background and the customers receive a report in a formatted Word file which can be shared with colleagues.
"We are very pleased to release this new "pay-as-you-go" product," said Julie Bryant, GeneGo's VP of Business Development. "We developed it based on many requests from our "Google-generation" customers who want the basic analysis done "within 30 minutes with one click." The trick was to combine the "ease of use" functionality with high quality analysis GeneGo is known for and sophistication of algorithms necessary for analysis of genome-wide datasets accessing the highest quality content in MetaCore(TM)"
"1-2-3 Workflow(TM) is not about stripping-down functions of our larger product, MetaCore," says Tatiana Nikolskaya, GeneGo's President and CSO. "You can consider it as a "condensed wisdom" of our data mining projects run in house in several disease areas and toxicity for several years. We wrapped this knowledge and "know how" up into a workflow with several knowledge ontologoies for enrichment analysis, the most advanced network building algorithms we have and our experience in finding the most relevant biomarkers and targets."
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
Source: GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo, Inc., +1-858-756-7996, email@example.com
Web site: www.genego.com/